{"schema_version":"secwatch.filing_event.v1","accession":"0001062993-25-002033","form_type":"8-K","ticker":"MDCX","cik":"0001997296","company_name":"Medicus Pharma Ltd.","filed_at":"2025-02-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:05.740500+00:00","generated_at":"2026-05-26T23:32:07.591623+00:00","sec_items":["1.01","3.02","8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Medicus Pharma enters $15M equity purchase agreement with Yorkville; plans TSXV delisting","bullets":["Standby Equity Purchase Agreement with Yorkville for up to $15M over 36 months; shares sold at 97% of market price.","Proceeds to fund Phase 2 BCC trial, expand to pivotal trial and other non-melanoma skin diseases.","Yorkville received $25k structuring fee and 105,840 commitment shares.","Board approved voluntary delisting from TSXV; shares continue on Nasdaq (MDCX).","Drawdowns require effective SEC registration statement; 19.99% cap and 4.99% beneficial ownership limit apply."],"urls":{"canonical":"https://secwatch.observer/filing/0001062993-25-002033","json":"https://secwatch.observer/filing/0001062993-25-002033.json","markdown":"https://secwatch.observer/filing/0001062993-25-002033.md","text":"https://secwatch.observer/filing/0001062993-25-002033.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325002033/0001062993-25-002033-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1997296/000106299325002033/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-26T23:32:07.591623+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}